UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: May 2015
Commission file number: 001-36578
BIO BLAST PHARMA LTD.
(Translation of registrant's name into English)
37 Dereh Menechem Begin St., 15th Floor
Tel Aviv 6522042 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
Results of the Annual General Meeting of Shareholders
At the annual general meeting of shareholders held on May 5, 2015, the shareholders of Bio Blast Pharma Ltd. approved all agenda items as originally proposed.
This Report of Foreign Private Issuer on Form 6-K of the Registrant is incorporated by reference into the registration statement on Form S-8 (File No. 333-203114) of the Registrant, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Bio Blast Pharma Ltd.
| ||
| Name: Colin Foster | ||
| Chief Executive Officer and President |
Date: May 5, 2015